Global Molecular Biology Enzymes, Kits and Reagents Market Size

Molecular Biology Enzymes Kits & Reagents Market Analysis

The Molecular Biology Enzymes, Kits, and Reagents Market is poised to grow at a CAGR of 10.5% during the forecast period (2022 - 2027).

The emergence of the COVID-19 pandemic has had an adverse effect on the world economy and the healthcare system. The lockdown all over the globe has affected the supply chain of pharmaceuticals, medical devices, and biotechnological products. There is a significant impact on the studied market due to the increasing demand for clinical diagnostics. For instance, according to an article published in the Antibiotics journal, in March 2022, titled' The Impact of Multiplex PCR in Diagnosing and Managing Bacterial Infections in COVID-19 Patients Self-Medicated with Antibiotics', multiplex PCR, a powerful and efficient tool, is used to diagnose SARS-CoV-2 infections and that has applications for bacterial identification, as well as determining bacterial resistance to antibiotics. Due to the increasing number of COVID-19 cases, the pharmaceutical and biotechnology companies are focusing on developing RT-PCR kits and assays for detecting coronavirus in patients which is expected to increase the demand for molecular biology enzymes, kits and reagents. For instance, BioGenexlaunches a direct RT-PCR kit that detects all variants of Covid-19 including Omicron double-quick, in the United States. The kit detects the Omicron without RNA extraction in half time than standard PCR. Thus, COVID-19 has impacted the market growth.

Certain factors that are propelling the market growth are the rising incidence of infectious diseases and genetic disorders, increasing research and development activities in the life science industry, and growing technology advancements.

The rising burden of infectious diseases and genetic disorders is the key factor driving the market growth. For instance, according to a survey conducted by the World Health Organization, between 24th January 2022 to 06th February 2022, approximately 12,368 individuals were positive for influenza viruses, of which 8,423 (68.1%) were typed as influenza A and 3,945 (31.9%) as influenza B. Of sub-typed influenza, A viruses, 171 (6.4%) were influenza A (H1N1) pdm09 and 2,483 (93.6%) were influenza A (H3N2). Thus, with the high prevalence of the different types of influenza globally, more technologically advanced products are required, which may drive the market studied during the forecast period.

Additionally, according to the data published by the World Health Organization in the Global Tuberculosis Report 2021, most of the tuberculosis cases were found in the World Health Organization (WHO) regions of South-East Asia (43%), Africa (25%), and the Western Pacific (18%), and lesser numbers of tuberculosis cases were found in Eastern Mediterranean (8.3%), the Americas (3.0%) and Europe (2.3%). Similarly, according to the World Health Organization (WHO) data published in 2021, Sub-Saharan Africa is projected to endure the burden of malaria, accounting for approximately 95% of all malaria cases and 96% of all deaths in 2020. Thus, growing cases of infectious diseases are expected to increase the demand for molecular biology enzymes and kits for diagnosis and therapeutic purposes, thereby propelling market growth.

Similarly, as per the data published by Nationwide Children's, in July 2021, more than 6,000 babies are born with down syndrome in the United States each year. Thus, the high number of babies born with down syndrome is expected to increase the demand for molecular biology kits and reagents, for testing purpose, which in turn is anticipated to propel the market growth.

Furthermore, the rising technological advancements are expected to increase market growth over the forecast period. For instance, in March 2022, Kaneka Corporation KANEKA RT-PCR Kit, SARS-CoV-2 (Omicron/Delta) ver.2, a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), Stealth Omicron (BA.2), and Delta variants of COVID-19. This test kit uses a proprietary reagent developed using Kaneka's molecular testing-related technologies to detect the presence of three variants with a single PCR test. Also, in November 2021, Genes2Me launched a molecular biology product range to accelerate and support bioscience research under the 'Made in India' initiative. The newly launched range includes enzyme technology, cloning, next-generation sequencing, and polymerase chain reaction among other product categories.

However, the high costs and limited reimbursement for genetic testing are expected to restrain the market growth over the forecast period.